Standardization ensures consistent site-level performance, supports label claims tied to biomarker positivity or pharmacodynamic engagement, and accelerates payer adoption by clarifying patient benefit, as seen in FLT3-mutant AML trials (Perl, 2025). This evidence concerns the gene FLT3 and acute myeloid leukemia.